Showing results (91-100 of 683) with videos related to
Sort By:
Pageof 69
Current Opinion in Molecular Therapeutics|November 7, 2003
Inflammatory bowel disorders: gene therapy solutionsStefan Wirtz, Markus F NeurathVisceral Medicine|March 11, 2021
SARS-CoV-2 Virus Manifestations in the Gastrointestinal Tract: Therapeutic ImplicationsAndré Jefremow, Markus F NeurathInnere Medizin (Heidelberg, Germany)|January 20, 2025
[Update on the pathophysiology, prediction and prevention of inflammatory bowel diseases]Sarah Fischer, Markus F NeurathJournal of Crohn'S & Colitis|May 13, 2022
IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical RealityRaja Atreya, Markus F NeurathMethods in Molecular Biology (Clifton, N.J.)|June 2, 2016
Oxazolone-Induced Colitis as a Model of Th2 Immune Responses in the Intestinal MucosaBenno Weigmann, Markus F NeurathClinical Pharmacology and Therapeutics|July 13, 2017
Precision Medicine in Inflammatory Bowel DiseasesSarah Fischer, Markus F NeurathCytokine & Growth Factor Reviews|July 18, 2015
Interleukin-12: Functional activities and implications for diseaseSebastian Zundler, Markus F NeurathNature Reviews. Gastroenterology & Hepatology|April 1, 2026
Pathophysiology of colitis-associated colorectal cancerClemens Neufert, Markus F NeurathBMC Gastroenterology|April 16, 2020
Baseline levels of dynamic CD4+ T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort studyClarissa Allner, Michaela Melde, Emily Becker, et al.Therapeutic Advances in Gastroenterology|December 6, 2021
α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitisMichaela Melde, Tanja M Müller, Ines Schneider, et al.Pageof 69